John Chiminski Buys Shares of QDEL $QDEL

Key Points

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

John Chiminski, insider at QuidelOrtho Corporation ($QDEL), bought 1,109 shares at an average price of $0. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.

QuidelOrtho Corporation Stock Up 23.7%

Shares of QuidelOrtho Corporation ($QDEL) traded around $18.23 on Tuesday, up 23.7% for the day.

Last price$18.23
Market cap$989.54M
Forward P/E10.01
PEG ratio2.06
Beta0.69
52-week low$9.92
52-week high$35.58
50-day MA$15.85
200-day MA$19.61
Current ratio1.39
Quick ratio0.60
Debt-to-equity1.73

QuidelOrtho Corporation Earnings

EPS (ttm)-$15.11
Revenue (ttm)$2.67B
Revenue growth2.80%
Net margin-39.20%
Return on equity-45.91%
Next earningsNov 5, 2026

Analysts Set New Price Targets

ConsensusHold
Average target$14.67
High target$20
Low target$12
Analysts covering3

About QuidelOrtho Corporation

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.

ExchangeNasdaqGS
SectorHealthcare
IndustryMedical Devices
HeadquartersSan Diego, CA
CEOMr. Brian J. Blaser
Employees6,500

Get QuidelOrtho Corporation alerts

New 13F filings, insider trades, and analyst moves on $QDEL, sent to your inbox. Free, and you can unsubscribe anytime.

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.